The Startup Aspirin: SAFEs Ease Fundraising Pain, But Read the Fine Print First

Ling Kong unpacks the promise and pitfalls of SAFEs in his latest piece for Crunchbase News. In “The Startup Aspirin: SAFEs Ease Fundraising Pain, But Read the Fine Print First,” Ling explores how these streamlined agreements have become the go-to vehicle for early-stage capital—favored for their speed and simplicity—yet come with significant trade-offs around dilution, valuation caps, and investor protections. With nearly 90% of Q3 2024 pre-priced rounds raised via SAFEs, Ling’s article is essential reading for founders navigating today’s venture landscape.